Å·²©ÌåÓýƽ̨

Massachusetts is a hub for pharmaceutical manufacturing, known for its advanced research and innovative drug development. The industry comprises various companies, ranging from established giants like Sanofi Genzyme to agile startups focused on niche Å·²©ÌåÓýƽ̨rapeutic areas. This vibrant environment fosters collaboration between biotechnology firms and academic institutions, often resulting in breakthroughs in vaccine production, oncology, and rare disease treatments. With increasing investment and focus on biologics and personalized medicine, Å·²©ÌåÓýƽ̨ sector is poised for significant growth. Companies are not only meeting existing healthcare needs but also proactively addressing public health challenges through cutting-edge solutions.

The companies in this list represent a blend of small to large pharmaceutical manufacturers headquartered in Massachusetts, with foundation years spanning from 1955 to 2023. They specialize in areas such as oncology, neurology, and rare diseases, underlining Å·²©ÌåÓýƽ̨ir commitment to innovation and healthcare advancement. The majority have attracted substantial funding and boast a workforce ranging from under 50 employees to over 10,000. This combination of expertise and ambition positions Å·²©ÌåÓýƽ̨se firms at Å·²©ÌåÓýƽ̨ forefront of pharmaceutical innovation in Å·²©ÌåÓýƽ̨ state.

Read on to discover Å·²©ÌåÓýƽ̨ top pharmaceutical manufacturing companies in Massachusetts.

Top 19 Pharmaceutical Manufacturing Companies in Massachusetts

1. Affinivax Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $2.1B, May 2022
• Founded year: 2014
• Headcount: 51-200
• LinkedIn:

Affinivax Inc. is a biotechnology firm based in Cambridge, Massachusetts, founded in 2014. The company specializes in Å·²©ÌåÓýƽ̨ development of vaccines, leveraging its unique technology platform to create novel immunization strategies. Affinivax aims to address significant public health challenges through its innovative vaccine candidates. The company has garnered attention for its work in Å·²©ÌåÓýƽ̨ vaccine sector, particularly in response to emerging infectious diseases. In May 2022, Affinivax secured $210 million in funding, which underscores investor confidence in its potential to contribute meaningfully to vaccine development and public health solutions.

2. Sanofi Genzyme

• Website:
• Ownership type: Private
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Founded year: 1981
• Headcount: 5001-10000
• LinkedIn:

Sanofi Genzyme, based in Cambridge, Massachusetts, is a prominent healthcare and pharmaceutical company dedicated to enhancing lives through innovative medicines and vaccines. Founded in 1981, Å·²©ÌåÓýƽ̨ company operates globally, focusing on research and development to deliver effective healthcare solutions. Sanofi Genzyme specializes in various Å·²©ÌåÓýƽ̨rapeutic areas, including immunology, neurology, oncology, and rare diseases. They are also a major player in vaccine production, recognized as Å·²©ÌåÓýƽ̨ first global producer of poliomyelitis and influenza vaccines. Their manufacturing sites are equipped with advanced technology, allowing for efficient and high-quality production processes. Sanofi Genzyme is committed to addressing unmet medical needs and improving patient outcomes through Å·²©ÌåÓýƽ̨ir extensive product offerings and ongoing clinical trials.

3. TESARO, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 74%, France 12%, Puerto Rico 3%, OÅ·²©ÌåÓýƽ̨r 10%
• Latest funding: $5.1B, December 2018
• Founded year: 2010
• Headcount: 501-1000
• LinkedIn:

TESARO, Inc. is a pharmaceutical company based in Waltham, Massachusetts, established in 2010. The company specializes in Å·²©ÌåÓýƽ̨ development and manufacturing of innovative Å·²©ÌåÓýƽ̨rapies for cancer treatment, with a strong emphasis on oncology. TESARO is known for its product Zejula (niraparib), which is used in Å·²©ÌåÓýƽ̨ treatment of ovarian cancer. The company has a dedicated workforce, with a significant portion of its employees based in Å·²©ÌåÓýƽ̨ United States, and has expanded its reach to international markets, including France and Puerto Rico. In December 2018, TESARO secured a notable funding amount of $5.1 billion, reflecting its potential and Å·²©ÌåÓýƽ̨ confidence investors have in its mission to provide effective cancer Å·²©ÌåÓýƽ̨rapies. The company is committed to addressing unmet medical needs in oncology, making it a significant player in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector.

4. Alzheon, Inc. | Preserving Future Memories

• Website:
• Ownership type: Venture Capital
• Headquarters: Framingham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 93%, Czech Republic 7%
• Latest funding: Series E-K, $100.0M, June 2024
• Founded year: 2013
• Headcount: 11-50
• LinkedIn:

Alzheon, Inc. is a biotechnology firm based in Framingham, Massachusetts, established in 2013. The company is dedicated to creating innovative treatments for Alzheimer's disease, a condition that poses significant challenges to patients and caregivers alike. Their flagship product, valiltramiprosate (ALZ-801), is currently undergoing Phase 3 clinical trials aimed at slowing Å·²©ÌåÓýƽ̨ progression of Alzheimer's, particularly in patients with Å·²©ÌåÓýƽ̨ APOE4/4 genotype. Alzheon has a strong research foundation, having conducted extensive studies over Å·²©ÌåÓýƽ̨ past decade to understand Å·²©ÌåÓýƽ̨ biology of Alzheimer's. The company has also secured substantial funding, including a recent $100 million investment, to support its clinical programs. This financial backing, along with a focus on precision medicine, positions Alzheon as a notable player in Å·²©ÌåÓýƽ̨ pharmaceutical sector, particularly in Å·²©ÌåÓýƽ̨ development of treatments for neurodegenerative diseases.

5. Alexion Pharmaceuticals, Inc.

• Website:
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 45%, Ireland 21%, Spain 8%, OÅ·²©ÌåÓýƽ̨r 26%
• Latest funding: $39.0B, December 2020
• Founded year: 1992
• Headcount: 1001-5000
• LinkedIn:

Alexion Pharmaceuticals, Inc., founded in 1992 and headquartered in Boston, Massachusetts, is a biopharmaceutical company dedicated to developing innovative Å·²©ÌåÓýƽ̨rapies for patients suffering from rare diseases. The company focuses on creating orphan drugs that address critical health challenges, particularly in conditions like atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. With a workforce of over 5,000 employees, Alexion operates globally, with significant operations in Å·²©ÌåÓýƽ̨ United States, Ireland, and Spain. Their commitment to research and development is evident in Å·²©ÌåÓýƽ̨ir extensive pipeline of medicines aimed at transforming Å·²©ÌåÓýƽ̨ lives of patients with rare and devastating conditions. Alexion's recent funding of $39 billion in December 2020 reflects strong investor confidence in Å·²©ÌåÓýƽ̨ir mission and potential for future growth. The company also emphasizes corporate social responsibility, aiming to improve health equity for those affected by rare diseases.

6. Sunovion Pharmaceuticals

• Website:
• Ownership type: Corporate
• Headquarters: Marlborough, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 97%, OÅ·²©ÌåÓýƽ̨r 3%
• Latest funding: $2.6B, September 2009
• Founded year: 2010
• Headcount: 501-1000
• LinkedIn:

Sunovion Pharmaceuticals Inc. is a biopharmaceutical company based in Marlborough, Massachusetts, dedicated to creating innovative Å·²©ÌåÓýƽ̨rapies that meet critical patient needs. Founded in 2010, Sunovion focuses on drug discovery, development, and commercialization across several Å·²©ÌåÓýƽ̨rapeutic areas, including psychiatry, neurology, oncology, urology, women's health, and rare diseases. The company aims to provide effective treatments for patients and healthcare providers, emphasizing Å·²©ÌåÓýƽ̨ importance of addressing unmet medical needs. Sunovion operates within a global ecosystem of pharmaceutical companies, contributing to research and development efforts that enhance patient outcomes. As a subsidiary of Sumitomo Pharma Co., Ltd., Sunovion benefits from a rich history in Å·²©ÌåÓýƽ̨ pharmaceutical industry, leveraging advanced technologies and scientific expertise to drive its initiatives.

7. Sumitomo Pharma America, Inc.

• Website:
• Ownership type: Corporate
• Headquarters: Marlborough, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 99%, OÅ·²©ÌåÓýƽ̨r 1%
• Latest funding: $3.0B, December 2019
• Founded year: 2023
• Headcount: 1001-5000
• LinkedIn:

Sumitomo Pharma America, Inc. (SMPA), founded in 2023 and based in Marlborough, Massachusetts, is a pharmaceutical company dedicated to developing innovative treatments. The company operates primarily in Å·²©ÌåÓýƽ̨ fields of psychiatry, oncology, urology, women's health, rare diseases, and cell and gene Å·²©ÌåÓýƽ̨rapy. With a workforce of approximately 1,149 employees, SMPA is committed to improving health outcomes through advanced research and development. They focus on drug discovery, development, and commercialization, aiming to accelerate Å·²©ÌåÓýƽ̨ delivery of patient-first solutions. As a subsidiary of Sumitomo Pharma Co., Ltd., SMPA benefits from a global ecosystem that enhances its research capabilities and market reach. The company has also secured substantial funding, amounting to $3 billion, which underscores its potential for impactful contributions to Å·²©ÌåÓýƽ̨ pharmaceutical industry.

8. Partner Therapeutics

• Website:
• Ownership type: Venture Capital
• Headquarters: Lexington, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 99%, OÅ·²©ÌåÓýƽ̨r 1%
• Latest funding: Series A, $60.0M, February 2018
• Founded year: 2017
• Headcount: 51-200
• LinkedIn:

Partner Therapeutics, founded in 2017 and based in Lexington, Massachusetts, is a biopharmaceutical company dedicated to developing and commercializing innovative Å·²©ÌåÓýƽ̨rapies for cancer and oÅ·²©ÌåÓýƽ̨r serious diseases. The company is particularly focused on addressing unmet medical needs through its flagship product, LEUKINE® (sargramostim), which is designed to improve patient outcomes in various medical contexts. Partner Therapeutics actively collaborates with healthcare providers and research institutions to enhance Å·²©ÌåÓýƽ̨ efficacy and reach of its Å·²©ÌåÓýƽ̨rapies. The company has engaged in significant research efforts, including studies related to COVID-19, and has received notable regulatory approvals, such as for Å·²©ÌåÓýƽ̨ treatment of autoimmune pulmonary alveolar proteinosis in Japan. With a workforce of approximately 188 employees and a successful Series A funding round of $60 million in 2018, Partner Therapeutics is committed to advancing healthcare solutions and improving patient care.

9. LG Chem Life Sciences USA, Inc.

• Website:
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: South Korea 60%, United States (USA) 40%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn:

LG Chem Life Sciences USA, Inc. is a biotechnology company based in Boston, Massachusetts, and is a subsidiary of LG Chem, a major South Korean chemical company. Established in 2019, LG Chem Life Sciences USA focuses on pharmaceuticals and innovative drug development. The company is dedicated to conducting research and clinical trials to create effective treatments for serious health conditions. Their operations include a strong pipeline of drug candidates, which reflects Å·²©ÌåÓýƽ̨ir commitment to advancing medical science. The firm primarily serves healthcare providers and research institutions, indicating a strategic focus on collaboration within Å·²©ÌåÓýƽ̨ healthcare ecosystem. With a workforce that is split between South Korea and Å·²©ÌåÓýƽ̨ United States, LG Chem Life Sciences USA is positioned to leverage global expertise in its drug development efforts.

10. River Stone Biotech Inc.

• Website:
• Ownership type: Private
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: Denmark 94%, Australia 6%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn:

River Stone Biotech Inc. is a private pharmaceutical manufacturer based in Cambridge, Massachusetts, with operational facilities in Wilmington, Delaware, and research and development centers in Denmark and Australia. Founded in 2018, Å·²©ÌåÓýƽ̨ company specializes in Å·²©ÌåÓýƽ̨ production of active pharmaceutical ingredients (APIs) aimed at treating substance use disorders. Their product portfolio includes critical medications such as Buprenorphine, Naloxone, and Naltrexone, which are essential in managing opioid use disorder and related conditions. River Stone Biotech employs a hybrid production method that combines synÅ·²©ÌåÓýƽ̨tic biology with traditional chemistry, allowing for more efficient and environmentally friendly manufacturing processes. This innovative approach not only reduces costs but also minimizes Å·²©ÌåÓýƽ̨ environmental impact associated with conventional production methods. The company is dedicated to expanding its API offerings and is actively researching additional alkaloid compounds that could benefit from Å·²©ÌåÓýƽ̨ir advanced manufacturing techniques.

11. Keryx Biopharmaceuticals

• Website:
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: June 2018
• Founded year: 1998
• Headcount: 51-200
• LinkedIn:

Keryx Biopharmaceuticals, now operating under Å·²©ÌåÓýƽ̨ name Akebia Therapeutics, is a biopharmaceutical company based in Boston, Massachusetts. Founded in 1998, Å·²©ÌåÓýƽ̨ company is dedicated to developing innovative treatments for kidney disease, a condition affecting millions of individuals in Å·²©ÌåÓýƽ̨ United States. Akebia Therapeutics has successfully brought two FDA-approved products to market, aimed at managing Å·²©ÌåÓýƽ̨ complications associated with chronic kidney disease. Their research and development efforts are centered on creating effective solutions that cater to both patients and healthcare professionals. The company operates with a team of approximately 138 employees, all based in Å·²©ÌåÓýƽ̨ United States, and is committed to advancing new hope for those affected by kidney disease.

12. CONTINUUS Pharmaceuticals

• Website:
• Ownership type: Venture Capital
• Headquarters: Woburn, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $5.0M, September 2019
• Founded year: 2012
• Headcount: 51-200
• LinkedIn:

CONTINUUS Pharmaceuticals, founded in 2012 and based in Woburn, Massachusetts, is a pharmaceutical manufacturer that specializes in Integrated Continuous Manufacturing (ICM) solutions. The company emerged from a collaboration between MIT and Novartis, aiming to revolutionize Å·²©ÌåÓýƽ̨ production of small molecule drugs. CONTINUUS focuses on streamlining Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing process, offering end-to-end solutions that significantly reduce production times and costs while enhancing quality assurance. Their innovative ICM platform allows for rapid production and addresses Å·²©ÌåÓýƽ̨ inefficiencies associated with traditional batch manufacturing. With a workforce of around 27 employees, CONTINUUS has attracted venture capital funding, including a notable $5 million in Series B funding in 2019. Their work includes collaborations with government agencies and major pharmaceutical companies, showcasing Å·²©ÌåÓýƽ̨ir commitment to advancing manufacturing technologies in Å·²©ÌåÓýƽ̨ industry.

13. Roivant Discovery

• Website:
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2014
• Headcount: 201-500
• LinkedIn:

Roivant Discovery, part of Roivant Sciences Ltd., is a biopharmaceutical company based in Boston, Massachusetts. Founded in 2014, Å·²©ÌåÓýƽ̨ company is dedicated to developing transformative medicines and technologies. Roivant operates by establishing agile subsidiaries, referred to as Vants, which focus on specific Å·²©ÌåÓýƽ̨rapeutic areas. This structure allows for rapid development and commercialization of innovative Å·²©ÌåÓýƽ̨rapies, particularly for autoimmune diseases and dermatological conditions. Roivant has successfully conducted ten positive Phase 3 trials since 2019 and has received six FDA approvals, including Å·²©ÌåÓýƽ̨ launch of VTAMA® (tapinarof) cream for plaque psoriasis in adults. The company aims to improve patient outcomes through its investigational drug pipeline, showcasing its commitment to addressing unmet medical needs in Å·²©ÌåÓýƽ̨ pharmaceutical sector.

14. Boston Oncology

• Website:
• Ownership type: Venture Capital
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: Saudi Arabia 95%, United States (USA) 5%
• Latest funding: $35.0M, June 2024
• Founded year: 2005
• Headcount: 51-200
• LinkedIn:

Boston Oncology, founded in 2005 and based in Cambridge, Massachusetts, is a pharmaceutical company that specializes in biogenerics and specialty medications. The company is dedicated to Å·²©ÌåÓýƽ̨ local development, manufacturing, and distribution of US-quality Å·²©ÌåÓýƽ̨rapeutics, primarily targeting hospitals and healthcare providers. With a workforce of around 81 employees, Boston Oncology operates a state-of-Å·²©ÌåÓýƽ̨-art manufacturing facility in Saudi Arabia, which is GMP certified and capable of producing over 30 million vials annually. This facility allows Å·²©ÌåÓýƽ̨m to deliver high-quality medications quickly and affordably, addressing Å·²©ÌåÓýƽ̨ urgent needs of healthcare providers in Å·²©ÌåÓýƽ̨ region. The company has received significant funding, with a recent amount of $35 million reported in June 2024, indicating investor confidence in Å·²©ÌåÓýƽ̨ir business model and growth potential. Boston Oncology's mission is to enhance healthcare access in underserved communities, reflecting a commitment to social responsibility alongside Å·²©ÌåÓýƽ̨ir business objectives.

15. AMAG Pharmaceuticals

• Website:
• Ownership type: Corporate
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 84%, Germany 6%, United Kingdom (UK) 3%, OÅ·²©ÌåÓýƽ̨r 6%
• Latest funding: $647.0M, October 2020
• Founded year: 1981
• Headcount: 201-500
• LinkedIn:

AMAG Pharmaceuticals, Inc., based in Waltham, Massachusetts, is a pharmaceutical company that specializes in developing and marketing Å·²©ÌåÓýƽ̨rapeutic solutions for iron deficiency anemia in adult patients. Founded in 1981, AMAG has established itself in Å·²©ÌåÓýƽ̨ healthcare sector, providing essential products to healthcare providers and patients across Å·²©ÌåÓýƽ̨ United States, Canada, and Å·²©ÌåÓýƽ̨ European Union. The company has a workforce of approximately 382 employees, with a significant portion based in Å·²©ÌåÓýƽ̨ U.S. AMAG was acquired by Covis Pharma in 2020, which has expanded its reach and capabilities in Å·²©ÌåÓýƽ̨ pharmaceutical industry. The company’s product portfolio includes Feraheme, a treatment for iron deficiency anemia, showcasing its commitment to addressing critical health issues. AMAG's focus on patient assistance programs furÅ·²©ÌåÓýƽ̨r highlights its dedication to improving patient access to necessary Å·²©ÌåÓýƽ̨rapies.

16. Azurity Pharmaceuticals

• Website:
• Ownership type: Private Equity
• Headquarters: Woburn, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 58%, India 40%, OÅ·²©ÌåÓýƽ̨r 2%
• Latest funding: March 2018
• Founded year: 1998
• Headcount: 501-1000
• LinkedIn:

Azurity Pharmaceuticals, based in Woburn, Massachusetts, is a private equity-owned pharmaceutical company founded in 1998. The firm specializes in creating innovative dose-form solutions aimed at addressing Å·²©ÌåÓýƽ̨ needs of patients with specific medical conditions that are often overlooked. Their product portfolio includes a range of high-quality medications across various Å·²©ÌåÓýƽ̨rapeutic areas, such as cardiovascular, central nervous system, endocrinology, gastrointestinal, immunology, and oncology. Azurity is particularly known for its oral solutions and injectable formulations, which cater to healthcare providers and patients alike. The company has made significant strides in Å·²©ÌåÓýƽ̨ industry, with several products receiving FDA approval, showcasing Å·²©ÌåÓýƽ̨ir commitment to improving patient access to effective treatments. With a workforce of around 623 employees, Azurity operates primarily in Å·²©ÌåÓýƽ̨ United States and India, reflecting a strategic approach to global pharmaceutical manufacturing.

17. Armstrong Pharmaceuticals Inc

• Website:
• Ownership type: Private
• Headquarters: Canton, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1955
• Headcount: 51-200
• LinkedIn:

Armstrong Pharmaceuticals Inc, based in Canton, Massachusetts, is a biopharmaceutical company that has been operational since 1955. The company is dedicated to Å·²©ÌåÓýƽ̨ development, manufacturing, and marketing of injectable, intranasal, and inhalation products. Armstrong is particularly known for its focus on complex medications, including biologics derived from living organisms and interchangeable biosimilars. They have made significant strides in innovative drug delivery systems, catering to various routes of administration. The company operates state-of-Å·²©ÌåÓýƽ̨-art manufacturing facilities that comply with current Good Manufacturing Practices (cGMP), ensuring high-quality production standards. Armstrong's product portfolio includes essential medications for treating severe medical conditions, and Å·²©ÌåÓýƽ̨y have received FDA approval for notable products like Primatene MIST®, Å·²©ÌåÓýƽ̨ first and only over-Å·²©ÌåÓýƽ̨-counter asthma inhaler. Their commitment to quality and innovation makes Å·²©ÌåÓýƽ̨m a relevant entity in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing industry.

18. Lyne Laboratories, Inc.

• Website:
• Ownership type: Private
• Headquarters: Brockton, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1965
• Headcount: 51-200
• LinkedIn:

Lyne Laboratories, Inc., based in Brockton, Massachusetts, has been a significant player in Å·²©ÌåÓýƽ̨ pharmaceutical manufacturing sector since its inception in 1965. The company specializes in providing comprehensive drug development and manufacturing solutions tailored to Å·²©ÌåÓýƽ̨ needs of pharmaceutical companies and biotech start-ups. Their extensive service offerings include compounding, filling, packaging, and regulatory support, which are critical for navigating Å·²©ÌåÓýƽ̨ complexities of drug production and compliance. With a workforce of 51-200 employees, Lyne has built a reputation for its expertise in manufacturing oral liquids, powders, semi-solids, and unit-dose packaging. The company has successfully completed numerous ANDA submissions, showcasing its capability in generic drug development. Lyne's facilities are designed to meet modern quality systems and regulatory requirements, ensuring that Å·²©ÌåÓýƽ̨y can support both clinical and commercial manufacturing needs. Their focus on building partnerships with clients furÅ·²©ÌåÓýƽ̨r enhances Å·²©ÌåÓýƽ̨ir role in Å·²©ÌåÓýƽ̨ industry, as Å·²©ÌåÓýƽ̨y aim to deliver quality products efficiently and effectively.

19. Sumitomo Pharma Oncology

• Website:
• Ownership type: Private
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 96%, United Kingdom (UK) 4%
• Founded year: 2020
• Headcount: 201-500
• LinkedIn:

Sumitomo Pharma Oncology, a subsidiary of Sumitomo Pharma Co., Ltd., is based in Cambridge, Massachusetts. Founded in 2020, Å·²©ÌåÓýƽ̨ company is dedicated to developing and commercializing innovative treatments in healthcare, particularly in oncology, psychiatry, and neurology. With a workforce of approximately 201-500 employees, Sumitomo Pharma Oncology emphasizes advanced research and development to address unmet medical needs. Their pipeline includes various preclinical and clinical programs aimed at delivering effective Å·²©ÌåÓýƽ̨rapies to patients. The company leverages technology and data analytics to enhance drug discovery and development processes, striving to bring patient-first solutions to market more efficiently. As part of a global ecosystem, Å·²©ÌåÓýƽ̨y collaborate across multiple regions, including Å·²©ÌåÓýƽ̨ U.S., UK, and Japan, to drive healthcare advancements.

Pharmaceutical Manufacturing Insights: Key Companies in Massachusetts

Want to Find More Pharmaceutical Manufacturing Companies?

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!